Prof. Wassilios Meissner
Centre Hospitalier Universitaire de Bordeaux
Sevice de Neurologie/CHU de Bordeaux
Avenue de Magellan
Expertise of the participating organization:
We are involved since 10 years in the differential diagnosis, treatment, clinical research and clinical trials, and epidemiology on parkinsonism. We conducted epidemiological research on PD (population-based study in the elderly living in South-western France) in collaboration with the Department of Epidemiology, Public Health and Development- University of Bordeaux2 (INSERM U-330, Prof. Dartigues). We are currently leading a registry of MSA patients and a study of risk factors of MSA within a network of Neurologists in Aquitaine, South-western France. We have also a strong experience in experimental research on basal ganglia physiology and pathophysiology. Since 1 year, we are leading a research team on animal models of MSA (both rodents and primates) within the Neurophysiology Laboratory, University of Bordeaux2 (CNRS-UMR 5543, director Prof. Bioulac). Principal scientific personnel involved in the project : Imad Ghorayeb, MD: Assistant-Assistant en Physiologie (Lecturer in Physiology), PhD student, involved in experimental research on MSA animal models. Farid Yeklef, MD. Clinical Research Assistant, involved in MSA epidemiology research. Virginie Chrysostome, MD: Qualified in Neurology (residency completed), involved in MSA epidemiological research (preparing a University Diploma of Epidemiology). Chrystophe Sourgen: Clinical Research Technician (INSERM-U330), involved in MSA epidemiological research. Pierre Olivier Fernagut: Neuroscience Diploma Student, University of Bordeaux2, involved in experimental research on MSA animal models.
Recent publications relevant to the EMSA-SG:
Pavy-Le Traon A, Piedvache A, Perez-Lloret S, Calandra-Buonaura G, Cochen-De Cock V, Colosimo C, Cortelli P, Debs R, Duerr S, Fanciulli A, Foubert-Samier A, Gerdelat A, Gurevich T, Krismer F, Poewe W, Tison F, Tranchant C, Wenning G, Rascol O, Meissner WG, European MSASG. New insights into orthostatic hypotension in multiple system atrophy: a European multicentre cohort study. J Neurol Neurosurg Psychiatry 2016;87:554-561.
Meissner WG, Laurencin C, Tranchant C, Witjas T, Viallet F, Guehl D, Damier P, Houeto JL, Tison F, Eusebio A, Vital A, Streichenberger N, Lannes B, Maues de Paula A, Thobois S. Outcome of deep brain stimulation in slowly progressive multiple system atrophy: A clinico-pathological series and review of the literature. Parkinsonism Relat Disord 2016;24:69-75.
Bassil F, Fernagut PO, Bezard E, Pruvost A, Leste-Lasserre T, Hoang QQ, Ringe D, Petsko GA, Meissner WG. Reducing C-terminal truncation mitigates synucleinopathy and neurodegeneration in a transgenic model of multiple system atrophy. Proc Natl Acad Sci U S A 2016;113:9593-9598.
Barbagallo G, Sierra-Pena M, Nemmi F, Traon AP, Meissner WG, Rascol O, Peran P. Multimodal MRI assessment of nigro-striatal pathway in multiple system atrophy and Parkinson disease. Mov Disord 2016;31:325-334.
Renaud M, Perriard J, Coudray S, Sevin-Allouet M, Marcel C, Meissner WG, Chanson JB, Collongues N, Philippi N, Gebus O, Quenardelle V, Castrioto A, Krack P, N'Guyen K, Lefebvre F, Echaniz-Laguna A, Azulay JP, Meyer N, Labauge P, Tranchant C, Anheim M. Relevance of corpus callosum splenium versus middle cerebellar peduncle hyperintensity for FXTAS diagnosis in clinical practice. J Neurol 2015;262:435-442.
Laurens B, Constantinescu R, Freeman R, Gerhard A, Jellinger K, Jeromin A, Krismer F, Mollenhauer B, Schlossmacher MG, Shaw LM, Verbeek MM, Wenning GK, Winge K, Zhang J, Meissner WG. Fluid biomarkers in multiple system atrophy: A review of the MSA Biomarker Initiative. Neurobiol Dis 2015;80:29-41.
Bassil F, Monvoisin A, Canron MH, Vital A, Meissner WG, Tison F, Fernagut PO. Region-Specific Alterations of Matrix Metalloproteinase Activity in Multiple System Atrophy. Mov Disord 2015;30:1802-1812.
Auzou N, Dujardin K, Biundo R, Foubert-Samier A, Barth C, Duval F, Tison F, Defebvre L, Antonini A, Meissner WG. Diagnosing dementia in multiple system atrophy by applying Movement Disorder Society diagnostic criteria for Parkinson's disease dementia. Parkinsonism Relat Disord 2015;21:1273-1277.
Rey MV, Perez-Lloret S, Pavy-Le Traon A, Meissner WG, Tison F, Rascol O. A cross-sectional study on drug use in multiple system atrophy. CNS Drugs 2014;28:483-490.
Meissner WG, Flabeau O, Perez P, Taillard J, Marquant F, Dupouy S, Tison F, Philip P, Ghorayeb I. Accuracy of portable polygraphy for the diagnosis of sleep apnea in multiple system atrophy. Sleep Med 2014;15:476-479.
Ghorayeb I, Dupouy S, Tison F, Meissner WG. Restless legs syndrome in multiple system atrophy. J Neural Transm (Vienna) 2014;121:1523-1527.
Flabeau O, Meissner WG, Ozier A, Berger P, Tison F, Fernagut PO. Breathing variability and brainstem serotonergic loss in a genetic model of multiple system atrophy. Mov Disord 2014;29:388-395.
Fernagut PO, Meissner WG, Biran M, Fantin M, Bassil F, Franconi JM, Tison F. Age-related motor dysfunction and neuropathology in a transgenic mouse model of multiple system atrophy. Synapse 2014;68:98-106.
Fernagut PO, Dehay B, Maillard A, Bezard E, Perez P, Pavy-Le Traon A, Rascol O, Foubert-Samier A, Tison F, Meissner WG. Multiple system atrophy: a prototypical synucleinopathy for disease-modifying therapeutic strategies. Neurobiol Dis 2014;67:133-139.
Meissner WG, Foubert-Samier A, Dupouy S, Debs R, Gerdelat-Mas A, Cochen De Cock V, Schrag A, Rascol O, Tison F, Pavy-Le Traon A. Validation of the French version of the MSA health-related Quality of Life scale (MSA-QoL). Rev Neurol (Paris) 2013;169:53-58.
Mazere J, Meissner WG, Sibon I, Lamare F, Tison F, Allard M, Mayo W. [(123)I]-IBVM SPECT imaging of cholinergic systems in multiple system atrophy: A specific alteration of the ponto-thalamic cholinergic pathways (Ch5-Ch6). Neuroimage Clin 2013;3:212-217.
Lamare F, Mazere J, Attila M, Mayo W, De Clermont-Gallerande H, Meissner W, Fernandez P, Allard M. Improvement of in vivo quantification of [123I]-Iodobenzovesamicol in single-photon emission computed tomography/computed tomography using anatomic image to brain atlas nonrigid registration. Mol Imaging 2013;12:288-299.
Meissner WG, Foubert-Samier A, Dupouy S, Gerdelat-Mas A, Debs R, Marquant F, De Cock VC, Rascol O, Tison F, Pavy-Le Traon A. Assessment of quality of life with the multiple system atrophy health-related quality of life scale. Mov Disord 2012;27:1574-1577.
Fernagut PO, Vital A, Canron MH, Tison F, Meissner WG. Ambiguous mechanisms of dysphagia in multiple system atrophy. Brain 2012;135:e205; author reply e206.
Damon-Perriere N, Foubert-Samier A, De Cock VC, Gerdelat-Mas A, Debs R, Pavy-Le Traon A, Senard JM, Rascol O, Tison F, Meissner WG. Assessment of the Scopa-Aut questionnaire in multiple system atrophy: relation to UMSARS scores and progression over time. Parkinsonism Relat Disord 2012;18:612-615.
Meissner WG, Vital A, Ghorayeb I, Guehl D, Tison F. Dyspnea as first sign of autonomic failure in postmortem confirmed multiple system atrophy. Mov Disord 2010;25:1997-1998.
Flabeau O, Meissner WG, Tison F. Multiple system atrophy: current and future approaches to management. Ther Adv Neurol Disord 2010;3:249-263.
Damon-Perriere N, Tison F, Meissner WG. [Multiple system atrophy]. Psychol Neuropsychiatr Vieil 2010;8:179-191.
Lambrecq V, Krim E, Meissner W, Guehl D, Tison F. [Deep-brain stimulation of the internal pallidum in multiple system atrophy.]. Rev Neurol (Paris) 2008; 164: 398-402.
Lesage S, Janin S, Lohmann E, Leutenegger AL, Leclere L, Viallet F, et al. LRRK2 exon 41 mutations in sporadic Parkinson disease in Europeans. Arch Neurol 2007; 64: 425-30.
Tison F, Yekhlef F, Chrysostome V. Depression and self-reported depressive symptoms in multiple system atrophy compared to Parkinson's disease. Mov Disord 2006; 21: 1056-7.
Biancalana V, Toft M, Le Ber I, Tison F, Scherrer E, Thibodeau S, et al. FMR1 premutations associated with fragile X-associated tremor/ataxia syndrome in multiple system atrophy. Arch Neurol 2005; 62: 962-6.
Fernagut PO, Ghorayeb I, Diguet E, Tison F. In vivo models of multiple system atrophy. Mov Disord 2005; 20 Suppl 12: S57-63.
Ghorayeb I, Bioulac B, Tison F. Sleep disorders in multiple system atrophy. J Neural Transm 2005; 112: 1669-75.
Ghorayeb I, Yekhlef F, Bioulac B, Tison F. Continuous positive airway pressure for sleep-related breathing disorders in multiple system atrophy: long-term acceptance. Sleep Med 2005; 6: 359-62.
Krim E, Vital A, Macia F, Yekhlef F, Tison F. Atypical parkinsonism combining alpha-synuclein inclusions and polyglucosan body disease. Mov Disord 2005; 20: 200-4.
Chrysostome V, Tison F, Yekhlef F, Sourgen C, Baldi I, Dartigues JF. Epidemiology of multiple system atrophy: a prevalence and pilot risk factor study in Aquitaine, France. Neuroepidemiology 2004; 23: 201-8.
Yekhlef F, Ballan G, Macia F, Delmer O, Sourgen C, Tison F. Routine MRI for the differential diagnosis of Parkinson's disease, MSA, PSP, and CBD. J Neural Transm 2003; 110: 151-69.
Ghorayeb I, Yekhlef F, Chrysostome V, Balestre E, Bioulac B, Tison F. Sleep disorders and their determinants in multiple system atrophy. J Neurol Neurosurg Psychiatry 2002; 72: 798-800.
Tison F, Yekhlef F, Chrysostome V, Balestre E, Quinn NP, Poewe W, et al. Parkinsonism in multiple system atrophy: natural history, severity (UPDRS-III), and disability assessment compared with Parkinson's disease. Mov Disord 2002; 17: 701-9.